American Journal of Obstetrics & Gynecology Mfm最新文献_第2页

Letter to Editor regarding 'The association between uterine fibroid number and size and risk of preterm birth'.

IF 3.8 2区医学

American Journal of Obstetrics & Gynecology Mfm Pub Date : 2024-12-05 DOI: 10.1016/j.ajogmf.2024.101573

Wei-Zhen Tang, Yue Tang, Tai-Hang Liu

引用次数: 0

How the history of midwifery and obstetrics still affects what you do today in pregnancy care: the American Journal of Obstetrics & Gynecology MFM starts a new "Obstetrical history" series.

IF 3.8 2区医学

American Journal of Obstetrics & Gynecology Mfm Pub Date : 2024-12-03 DOI: 10.1016/j.ajogmf.2024.101514

Vincenzo Berghella, Emily S Miller, Molly Stout, Adam K Lewkowitz, Terri-Ann Bennett, Karin A Fox

引用次数: 0

Trustworthiness criteria for meta-analyses of randomized controlled studies: OBGYN journal guidelines. 随机对照研究荟萃分析的可信度标准：妇产科杂志指南》。

IF 3.8 2区医学

American Journal of Obstetrics & Gynecology Mfm Pub Date : 2024-12-01 Epub Date: 2024-10-10 DOI: 10.1016/j.ajogmf.2024.101481

引用次数: 0

Cervical length nomograms for singleton pregnancies: a large-scale gestational analysis. 单胎妊娠的宫颈长度提名图：大规模妊娠分析：单胎妊娠的大规模宫颈长度提名图。

IF 3.8 2区医学

American Journal of Obstetrics & Gynecology Mfm Pub Date : 2024-12-01 Epub Date: 2024-11-04 DOI: 10.1016/j.ajogmf.2024.101539

Doron Kabiri, Roie Alter, Joshua I Rosenbloom, Ofer Tadmor, Einav Kremer

引用次数: 0

Aspirin dosage for preeclampsia prophylaxis: an argument for 162 mg dosing.

IF 3.8 2区医学

American Journal of Obstetrics & Gynecology Mfm Pub Date : 2024-11-28 DOI: 10.1016/j.ajogmf.2024.101564

Maura E Jones Pullins, Kim A Boggess

引用次数: 0

Vaginal progesterone for prevention of preterm birth in women with a history of preterm birth regardless of cervical length: an argument for use: An argument.

IF 3.8 2区医学

American Journal of Obstetrics & Gynecology Mfm Pub Date : 2024-11-27 DOI: 10.1016/j.ajogmf.2024.101565

Charlette E Williams, Rupsa C Boelig

引用次数: 0

PPROM in the late preterm period: an argument against expectant management.

IF 3.8 2区医学

American Journal of Obstetrics & Gynecology Mfm Pub Date : 2024-11-27 DOI: 10.1016/j.ajogmf.2024.101562

Ghamar Bitar, Baha M Sibai

引用次数: 0

Non-severe hypertensive disorders of pregnancy and oral antihypertensive medications: An argument in favor of use: Treatment of Gestational Hypertension. 非严重妊娠高血压疾病与口服降压药：支持使用的论据：妊娠高血压的治疗。

IF 3.8 2区医学

American Journal of Obstetrics & Gynecology Mfm Pub Date : 2024-11-25 DOI: 10.1016/j.ajogmf.2024.101561

Lorena Carolina Martinez-King, Leah M Savitsky, Sherill Rose, Catherine Albright

{"title":"Non-severe hypertensive disorders of pregnancy and oral antihypertensive medications: An argument in favor of use: Treatment of Gestational Hypertension.","authors":"Lorena Carolina Martinez-King, Leah M Savitsky, Sherill Rose, Catherine Albright","doi":"10.1016/j.ajogmf.2024.101561","DOIUrl":"https://doi.org/10.1016/j.ajogmf.2024.101561","url":null,"abstract":"Hypertensive disorders of pregnancy are a common complication of pregnancy and a major contributor to both immediate and long-term morbidity and mortality. Recent data support the treatment of chronic hypertension during pregnancy to a blood pressure goal of <140/90 mmHg. Treatment of severe range blood pressures (≥160/110 mmHg) in the setting of gestational hypertension is recommended to prevent severe morbidity and mortality; however, there remains clinical equipoise regarding treatment of gestational hypertension with blood pressures ≥140/90 but <160/110. While there is limited data to support the treatment of gestational hypertension, we believe that treatment of gestational hypertension to a blood pressure of <140/90, similar to the recommendations for chronic hypertension, will lead to a reduction in severe maternal and neonatal morbidity and mortality related to hypertensive disorders of pregnancy. In this expert review, we summarize the available data regarding the treatment of gestational hypertension and offer recommendations for the treatment of gestational hypertension based on our clinical experience.","PeriodicalId":36186,"journal":{"name":"American Journal of Obstetrics & Gynecology Mfm","volume":" ","pages":"101561"},"PeriodicalIF":3.8,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142740871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vaginal progesterone for prevention of preterm birth in women with a history of preterm birth regardless of cervical length: an argument against use. 对有早产史的妇女使用阴道黄体酮预防早产（无论宫颈长度如何）：反对使用的理由。

IF 3.8 2区医学

American Journal of Obstetrics & Gynecology Mfm Pub Date : 2024-11-25 DOI: 10.1016/j.ajogmf.2024.101571

Anthony Melendez Torres, Sarahn Wheeler

{"title":"Vaginal progesterone for prevention of preterm birth in women with a history of preterm birth regardless of cervical length: an argument against use.","authors":"Anthony Melendez Torres, Sarahn Wheeler","doi":"10.1016/j.ajogmf.2024.101571","DOIUrl":"https://doi.org/10.1016/j.ajogmf.2024.101571","url":null,"abstract":"Preterm birth, defined as birth before 37 weeks of gestation, has a significant public health impact as the most frequent cause of neonatal death, and second most frequent cause of infant death at age <5 years. Given the unclear and likely multifactorial etiologic nature of preterm birth, interventions to address this condition have been elusive. Progesterone supplementation was once thought to be a promising strategy to reduce preterm birth among patients with a history of prior preterm birth. However, more recent data suggesting limited efficacy led the US Food and Drug Administration to revoke approval of 17-alpha hydroxyprogesterone caproate (17-OHPC). Vaginal progesterone supplementation remains controversial. Recently published meta-analyses evaluating large, pre-registered randomized controlled trials at low risk of bias and selective outcome reporting, have found recurrent preterm birth rates are not significantly reduced by vaginal progesterone supplementation in patients with a singleton gestation and prior history of spontaneous preterm delivery. Furthermore, studies reporting any benefit from vaginal progesterone in this patient population are noted to have smaller sample sizes, higher risk of bias and selective outcome reporting, and low external validity. As such, we argue against the universal use of vaginal progesterone supplementation for the prevention of recurrent preterm birth. VIDEO ABSTRACT.","PeriodicalId":36186,"journal":{"name":"American Journal of Obstetrics & Gynecology Mfm","volume":" ","pages":"101571"},"PeriodicalIF":3.8,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142740568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

"Inpatient pharmacological thromboprophylaxis in the antepartum period: an argument for universal thromboprophylaxis". "产前住院病人的血栓预防药物治疗：普及血栓预防的论据"。

IF 3.8 2区医学

American Journal of Obstetrics & Gynecology Mfm Pub Date : 2024-11-25 DOI: 10.1016/j.ajogmf.2024.101566

Julia Burd, Amanda Zofkie

{"title":"\"Inpatient pharmacological thromboprophylaxis in the antepartum period: an argument for universal thromboprophylaxis\".","authors":"Julia Burd, Amanda Zofkie","doi":"10.1016/j.ajogmf.2024.101566","DOIUrl":"https://doi.org/10.1016/j.ajogmf.2024.101566","url":null,"abstract":"Venous thromboembolism (VTE), a largely preventable condition, accounts for almost 15% of maternal mortalities. The physiologic changes of pregnancy, including quantitative changes in coagulation factors and compression of vasculature by the gravid uterus, cause an increase in risk of VTE, including deep vein thromboembolism (DVT), pulmonary embolism (PE), and stroke (CVA). Long term antepartum admission for preeclampsia, preterm prelabor rupture of membranes (PPROM) or other high-risk pregnancy needs present additional risk factors for VTE due to the patient's medical condition and their inpatient status. Given the near-universal support for anticoagulation in patients with a history of venous thromboembolism or high-risk thrombophilia, we will focus this work on patients generally considered low or moderate risk. As outpatients, we do not recommend anticoagulation for this lower risk population. However, with the increase in risk factors for VTE with prolonged admission, it is our general practice to discuss the risks, benefits, and alternatives of chemical VTE prophylaxis 72 hours after admission and recommend administration to all patients unless they have active vaginal bleeding or are at risk for imminent delivery. Here, we will argue why this strategy of universal VTE prophylaxis during antepartum admission with unfractionated heparin (UFH) or low-molecular weight heparin (LMWH) is ultimately in the best interest of patient safety.","PeriodicalId":36186,"journal":{"name":"American Journal of Obstetrics & Gynecology Mfm","volume":" ","pages":"101566"},"PeriodicalIF":3.8,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142740869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0